Auriemma Renata S, Pivonello Rosario, Ferreri Lucia, Priscitelli Prisco, Colao Annamaria
Ios-Coleman Medicina Futura Medical Center, Centro Direzionale, Naples 80143, Italy.
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, University "Federico II", via Sergio Pansini 5, Naples 80131, Italy.
Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97. doi: 10.1016/j.ecl.2014.10.007. Epub 2014 Nov 4.
Cabergoline (CAB) is widely used for the medical treatment of pituitary tumors, particularly those associated with hormone hypersecretion. Whether treatment with CAB is associated with an increased risk of clinically relevant cardiac valve disease in patients with pituitary tumors is still debated. In most studies, CAB has been found not associated with an increased risk of significant valvulopathy, and no correlation has been shown between valvular abnormalities and CAB duration or cumulative dose. This review provides an overview of the studies reporting on the outcome of CAB in terms of cardiac valve disease in patients with pituitary tumors.
卡麦角林（CAB）被广泛用于垂体肿瘤的医学治疗，尤其是那些与激素分泌过多相关的肿瘤。卡麦角林治疗是否会增加垂体肿瘤患者发生临床相关心脏瓣膜疾病的风险仍存在争议。在大多数研究中，已发现卡麦角林与显著瓣膜病风险增加无关，并且瓣膜异常与卡麦角林治疗持续时间或累积剂量之间未显示出相关性。本综述概述了关于垂体肿瘤患者心脏瓣膜疾病方面卡麦角林治疗结果的研究。
